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ABSTRACT
Objective: Home blood pressure (HBP) measurements are known as an important adjunct to office blood pressure (OBP) measurements in 
clinical practice. But little is known about the relationship between HBP and subclinical target organ damage (TOD) other than left ventricular 
hypertrophy (LVH). So we investigated the relationship of HBP measurements with subclinical TOD in untreated hypertensive patients.
Methods: We measured ambulatory blood pressure (ABP), HBP and OBP of 93 untreated hypertensive patients (men: 60 and women: 33, mean 
age, 49±13 years). The ABP was recorded for 24 hours, HBP was measured for one week, and OBP was measured at least in two visits. All BP 
measurements were taken using automatic BP measuring device. The parameters indicating subclinical TOD were the left-ventricular mass 
index (LVMI) by transthoracic echocardiography, urinary albumin excretion rate (AER), brachial ankle pulse-wave velocity (PWV), and carotid 
intima-media thickness (IMT).
Results: The LVMI was significantly correlated with systolic HBP and 24 hours systolic ABP, but not with OBP. The AER, PWV and IMT were also 
significantly correlated with systolic HBP and 24 hours systolic ABP. In a binary logistic regression analysis, systolic HBP, 24 hours systolic and 
diastolic ABP were the predictors of LVMI, AER and PWV (all p<0.05).
Conclusion: Our data suggest that HBP is as good as ABP monitoring and superior to OBP measurements in regard to their association with 
subclinical TOD. Therefore, HBP measurements give valuable information on the subclinical TOD in hypertensive patients in addition to ABP 
monitoring. (Anadolu Kardiyol Derg 2014; 14: 711-8)
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Home blood pressure is the predictor of subclinical target organ 
damage like ambulatory blood pressure monitoring in untreated 
hypertensive patients
Introduction
Hypertension is a strong, independent risk factor for cardio-
vascular disease (1). Generally, the diagnosis of hypertension is 
based on the traditional method of taking auscultatory measure-
ments (office blood pressure, OBP) in a clinical setting. However, 
because of the white-coat and the masked hypertensive phenom-
ena, OBP may be unrepresentative of the true blood pressure in 
about 30% of the patients who visit hypertension clinics (2). 
Actually current guidelines and recommendations suggest that 
diagnosis and treatment of hypertension should no longer be 
based on OBP alone, and that incorporation of out-of-office 
measurements should be mandatory (3, 4).
Previous studies showed that ambulatory blood pressure 
(ABP) and home blood pressure (HBP) measurements are more 
reproducible than OBP measurements (5). ABP measurements 
are more closely related to subclinical target organ damage (TOD) 
(6, 7) and a risk of cardiovascular events (8, 9). Other reports also 
suggested that HBP is useful in predicting hypertension-induced 
TOD, and is superior to carefully taken OBP measurements (10).
However, although several studies have reported the asso-
ciation of HBP with indices of subclinical TOD, evidence of the 
value of HBP in predicting subclinical TOD is still limited (11). 
Little is known about the relationship between HBP and hyper-
tensive subclinical TOD other than left ventricular hypertrophy 
(LVH). Apart from the studies of LVH, controversial results were 
present for assessing all the other TOD indices (12, 13). Therefore, 
we investigated the relationship of HBP measurements with all 
indices of subclinical TOD with a direct comparison versus OBP 
and ABP measurements in untreated hypertensive patients.
Methods
Study population
Untreated hypertensive patients aged 20 to 75 years with 
systolic OBP ≥140 mm Hg or diastolic OBP ≥90 mm Hg on two 
routine pre-study office visits were included. The patients had 
not received antihypertensive drug treatment for at least six 
months before joining the study. Patient exclusion criteria were 
systolic blood pressure (SBP) >200 mm Hg and/or diastolic blood 
pressure (DBP) >120 mm Hg anytime during the study and a his-
tory of secondary hypertension, congestive heart failure, coro-
nary artery disease, valvular heart disease, serum creatinine 
>1.5 mg/dL, overt proteinuria or hematuria, and the use of any 
drug known to influence blood pressure within four weeks 
before and during the study. All patients gave informed consent 
for study participation and we had the Ethic Committee report.
Blood pressure measurements
Blood pressure was measured in the office, at home, and with 
ambulatory monitoring. OBP was measured by trained physicians 
in two study visits, one week apart, using a validated oscillometric 
device with memory capacity (bladder size, 23x12 cm or 28x14 cm 
where appropriate; Omron HEM-705CP; Omron Healthcare GmbH, 
Hamburg, Germany). OBP measurements were performed at each 
visit after 5 min of sitting rest and with at least 1 min between 
recordings (14). HBP was self-monitored by patients who used 
the same device and cuff as for OBP measurements (Omron HEM-
705CP). The patients were trained and instructed to perform HBP 
measurements using the above mentioned device in duplicates, 
once in the morning (7:00-10:00 AM) and in the evening (6:00-9:00 
PM), after 5 min of sitting rest and with 1 min between readings, 
for six routine working days within two weeks (4). All patients 
were under a 24 hour non-invasive ABP monitoring with a vali-
dated oscillometric device (Tonoport V, GE healthcare, USA). 
Blood pressure monitoring was performed on working days with 
patients performing usual daily activities and refraining from 
heavy physical exercise. Blood pressure and heart rate readings 
were obtained every 15 min during the day (7:00 AM-11:00 PM) 
and every 30 min during the night (11:00 PM-7:00 AM). Patients 
were instructed to keep a diary of their activities and note the time 
they retired to bed, and ABP recordings were subdivided accord-
ingly into “awake” or “asleep” periods based on these diary 
entries, which practically coincided, in most patients, with arbi-
trarily defined day and night subperiods. Blood pressure variabil-
ity (BPV) was calculated as the standard deviation (SD) of mean 
awake and asleep SBP and DBP (15). BPV over 24 hours was 
obtained from the weighted average of day and night blood pres-
sure SD values (16).
Measurement of subclinical TOD: Left-ventricular mass 
index
The LVH becomes a preclinical disease and an independent 
risk factor for congestive heart failure, ischemic heart disease, 
arrhythmia, sudden death, and stroke (17). M-mode and two-
dimensional echocardiograms were performed approximately ten 
weeks after the initial assessment visits. Left ventricular mea-
surements were done from two-dimensionally guided M-mode 
tracings according to the recommendations of the American 
Society of Echocardiography (18). If an M-mode tracing was tech-
nically inadequate, linear measurements were performed from 
the two-dimensional study (19). Up to six echocardiographic 
cycles were measured and averaged. Left ventricular mass (LVM) 
was calculated using the corrected American Society of 
Echocardiography formula: 0.8x(1.04x[(interventricular septum 
thickness in diastole + left ventricular internal dimension in dias-
tole + posterior wall thickness in diastole)3 - left ventricular inter-
nal dimension in diastole3]) + 0.6. The LVM index (LVMI) was cal-
culated by dividing LVM by the estimated body surface area, cal-
culated from height and weight. The LVMI was also used to 
identify subjects with LVH, defined as LVMI ≥125 g/m2 for men and 
≥110 g/m2 for women (20).
Measurement of subclinical TOD: Urinary albumin
excretion rate
Microalbuminuria is a marker of high cardiovascular risk and 
the presence of microalbuminuria is also accompanied by an 
elevated risk of developing a progressive fall in glomerular filtra-
tion rate (GFR) (21). The urinary albumin excretion rate (AER) 
was assessed by means of the first urine sample of the morning. 
The AER was performed approximately ten weeks after the ini-
tial assessment visits. If the result was outside the normal limits, 
further determinations were made on 24 hours urine samples. 
The AER was measured with the immunoturbidimetric method 
(Mitsubishi Kagaku Iatron Inc., Tokyo, Japan). Microalbuminuria 
was defined as an AER of 15-150 μg/min, normoalbuminuria <15 
μg/min, and proteinuria >150 μg/min (22).
Measurement of subclinical TOD: Carotid-femoral pulse 
wave velocity
Current guidelines for the management of hypertension 
introduce the assessment of arterial stiffness by pulse wave 
velocity (PWV) as an index of hypertension-related cardiovas-
cular TOD (23). Arterial stiffness was determined by measuring 
the carotid-femoral PWV, using an automatic waveform analyzer 
with multi-element tonometry sensors (VP-2000, Colin CO. Ltd., 
Komaki, Japan). They were placed at the left carotid and the left 
femoral arteries for the recording of pressure waveforms of 
these arteries. This automatic waveform analyzer of form deter-
mines the upstroke of the wave and the pulse transit time on 
phase velocity theory (24). The distance that the pulse waves 
travels from the sensors at the carotid to the femoral artery was 
obtained based on the height by using the formula. The path 
lengths from the suprasternal notch to the carotid site and to the 
femur were obtained from superficial measurements. These 
measurements were performed approximately ten weeks after 
the initial assessment visits. Then the carotid-femoral PWV was 
automatically calculated by equation. The cut-off score of 18 m/
sec was determined as abnormal (25).
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Measurement of subclinical TOD: Carotid intima-media 
thickness 
The carotid intima-media thickness (IMT), as measured by 
B-mode ultrasound, is a surrogate marker for atherosclerosis and 
is an independent predictor of stroke and myocardial infarction 
(26). The carotid IMT was determined from a longitudinal ultraso-
nographic section through the carotid bulb and primary carotid. 
These measurements were performed approximately ten weeks 
after the initial assessment visits. For the examination, the patient 
was supine, with the neck extended slightly and the head directed 
away from the side of the examination. Longitudinal two-dimen-
sional images of the carotid arteries were obtained in the anterior, 
lateral, and posterior planes using a 7.5 MHz probe by two sonog-
raphers (Vivid 7; GE, Fairfield, Connecticut, USA) outside the 
Department of Patient Recruitment. Multiple measurements were 
taken from the distal 1 cm of the common carotid artery, from the 
adjoining carotid bulb, and from the proximal 1 cm of the internal 
carotid artery, on both the right and left sides. For each side, the 
mean values of two images were recorded, and the higher value 
was used in the analysis. A value 0.9 mm or higher was consid-
ered as abnormal (25).
Statistical analyses
Results were presented as mean±SD. Fisher’s exact test and 
independent-samples t-tests were used to compare proportions 
and means. Paired t-tests were used to test for differences in 
mean levels of the various blood pressure measurements. 
Pearson’s correlations were used to assess the associations 
between OBP, ABP, and HBP measurements with LVMI, AER, 
PWV, and IMT. To assess the independent predictive utility of the 
different blood pressure measurements, binary logistic regres-
sion models were estimated, including age and blood pressure 
measurements as primary predictors. Relationships between 
the different measurements of blood pressure and TOD were 
analyzed by linear regression with calculation of the coefficient 
of correlation after checking for a normal distribution using 
Shapiro-Wilks test. The chi-square test was employed to com-
pare the qualitative variables. Differences between values of 
coefficient of correlation were compared with Fisher’s exact 
tests. Statistical significance was defined by α=0.05, two-tailed. 
Statistical analyses were performed using SPSS version 13.0 
(SPSS, Inc., Chicago, IL USA).
Results
Baseline characteristics
Table 1 shows the characteristics of the study population. 
Ninety-three untreated hypertensive patients (60 men, 65%) 
were enrolled in the study. The mean age was 49±13 years, and 
mean body mass index was 24.3±2.9 kg/m2. The number of 
patients with previously diagnosed hypertension was 42 (45%). 
TOD parameters and average blood pressure values obtained by 
each measurement method are given also in Table 1. 
Relationship between mean BP Levels and indices of
subclinical TOD
The correlation coefficients of blood pressure measurement 
with subclinical TOD are presented in Table 2. The correlation 
coefficients of LVMI with systolic HBP was 0.33 (p<0.05), 24 
hours systolic ABP 0.42 (p<0.05), and asleep ABP (SBP/DBP) 
Variables Value (%)
Sex, men/women, n 60/33 (65/35)
Age, years 49±13
Body mass index, kg/m2 24.3±2.9
Associated conditions
Diabetes mellitus  6 (8)
Smoking 17 (22)
Dyslipidemia 5 (6)
Previous diagnosis of hypertension 42 (45)
Family history of premature cardiovascular 32 (34) 
disease
Target organ damage
LVMI, left-ventricular mass index, g/m2  81.9±16.3
AER, urinary albumin excretion rate, mg/g Cr  16.7±15.2
PWV, carotid-femoral pulse wave velocity, m/sec 14.8±2.6
IMT, carotid intima media thickness, mm 0.7±0.3
Blood pressure
Office SBP/DBP, mm Hg 142.6±11.3/88.6±7.4
Home SBP/DBP, mm Hg 131.3±11.4/82.1±8.8
24 hour Ambulatory SBP/DBP, mm Hg 139.4±11.7/90.7±9.5
Awake ambulatory SBP/DBP, mm Hg  142.7±12.1/93.5±10.0
Asleep ambulatory SBP/DBP, mm Hg  126.5±13.2/80.1±10.2
DBP - diastolic blood pressure; SBP - systolic blood pressure. 
Data are shown as mean±Standard Deviations (SD)
Table 1. Demographics and values of the patients
Blood pressure LVMI, AER, mg/g  PWV, IMT, 
 g/m2 Cr m/sec mm
Office
SBP/DBP, mm Hg 0.16/0.14 0.16/0.07 0.27*/-0.03 0.20/0.20
Home
 SBP/DBP, mm Hg 0.33**/0.17 0.25*/0.10 0.42**/0.07 0.26*/0.11
Ambulatory
24 hours
SBP/DBP, mm Hg 0.42**/0.32 0.08/-0.01 0.26*/0.13  0.38**/0.27
Awake
SBP/DBP, mm Hg 0.43/0.32 0.05/-0.03 0.25*/0.09  0.36**/0.23*
Asleep
SBP/DBP, mm Hg 0.35**/0.27* 0.12/0.02 0.21/0.17 0.30**/0.2*
DBP - diastolic blood pressure; SBP - systolic blood pressure; *P <0.05; **P<0.01
Table 2. Correlation coefficients between mean BP and TOD
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0.35/0.27 (p<0.05/0.01). However, the correlation between OBP 
(SBP/DBP) and LVMI was not statistically significant. Systolic 
HBP was also correlated with AER (r=0.25, p<0.05). The correla-
tion coefficients of PWV with systolic OBP was 0.27 (p<0.05), 
systolic HBP 0.42 (p<0.01), 24 hours systolic ABP 0.26 (p<0.05), and 
awake systolic ABP 0.25 (p<0.05). For IMT, systolic HBP (r=0.26, 
p<0.05), 24 hours systolic ABP (r=0.38, p<0.01), awake ABP (SBP/
DBP) (r=0.36, p<0.01/ r=0.23, p<0.05) and asleep ABP (SBP/DBP) 
(r=0.30, p<0.01/r=0.2, p<0.05) were significantly correlated. 
According to the indices of subclinical TOD, it showed the stron-
ger relationship with either the HBP or the ABP than with the OBP.
In order to further confirm, we performed binary logistic 
regression analysis for individual TOD parameters such as age, 
sex, smoking, diabetes, dyslipidemia, and all three BP mea-
surements. With cut-off values of LVMI ≥125 g/m2 (M) and ≥110 
g/m2 (W), the results are as shown in Table 3A. As Table 3B 
shows, systolic HBP and 24 hours systolic and diastolic ABP 
were significant predictors of LVMI after adjusting other fac-
tors. In the same way, for AER [cut-off values, ≥22 (M) or ≥31 
(F) mg/g Cr] and PWV (cut-off values, 18 m/sec), the results 
were similar as shown in Tables 4A, B and 5A, B. Systolic HBP 
and 24 hours systolic and diastolic ABP were statistically sig-
nificant predictors of AER and PWV, independent of other 
predictors.
Relationship between BPV and TOD
Table 6 shows coefficients of correlation between BPV and 
the indices of subclinical TOD. The correlation coefficients of 
LVMI with 24 hours systolic ABP variability (ABPV) was 0.25 
(p<0.05), and with asleep ABPV (systolic/diastolic ABPV) was 
0.30/0.24 (p<0.01/p<0.05). Systolic home BPV (HBPV) was signifi-
cantly correlated with PWV (r=0.30, p<0.01) and IMT (r=0.24, 
p<0.05). A binary logistic regression analysis for individual TOD 
parameters showed that systolic HBPV and 24 hours systolic 
ABPV were significant predictors of LVMI, AER, PWV and IMT 
(all p<0.05).
Discussion
The role of ABP monitoring in the management of hyperten-
sion and the prediction of cardiovascular events has been well 
established (2). Meanwhile, HBP measurements are recognized to 
share most of the advantages of ABP monitoring. Recent meta-
analysis of the evidence on the ability of HBP to subclinical TOD 
has been published, and it reported similar correlations of LVH 
with HBP (coefficients r=0.46/0.28, systolic/diastolic) as with ABP 
measurements (0.37/0.26, P=NS for difference vs. HBP) (10). 
However, apart from echocardiographic LVH, the evidence for 
other indices of subclinical TOD is rather weak and uncertain.
 Unstandardized coefficient Standardized 
  coefficient
 B SE Beta t P value
 SBP DBP SBP DBP SBP DBP SBP DBP SBP DBP
HBP 0.39 0.24 0.15 0.20 0.27 0.13 2.57 1.20 0.01 0.23
Age 0.13 0.21 0.14 0.14 0.11 0.17 0.94 1.51 0.35 0.14
Sex -8.27 -10.09 3.90 3.93 -0.24 -0.30 -2.12 -2.56 0.04 0.01
Smoking -5.46 -6.06 4.38 4.54 -0.13 -0.15 -1.25 -1.34 0.22 0.19
Diabetes 1.67 2.11 6.67 6.94 0.03 0.03 0.25 0.30 0.80 0.76
Dyslipidemia -1.69 -2.39 7.22 7.46 -0.02 -0.03 -0.23 -0.32 0.81 0.75
R-square (SBP/DBP)=0.163/0.103; Adjusted R-square (SBP/DBP)=0.112/0.049. Cut-off values of LVMI ≥125 g/m2 (M) and ≥110 g/m2 (W). B-blood; DBP - diastolic blood pressure;  
HBP - home blood pressure; SBP - systolic blood pressure
Table 3A. Regression analysis for predictors of LVMI [≥125 g/m2 (M) or ≥110 g/m2 (W)] using HBP and other variables
 Unstandardized coefficient Standardized 
  coefficient
 B SE Beta t P value
 SBP DBP SBP DBP SBP DBP SBP DBP SBP DBP
ABP, 24 h 0.53 0.47 0.15 0.20 0.39 0.28 3.50 2.33 0.0007 0.02
Age 0.15 0.18 0.14 0.14 0.12 0.15 1.14 1.32 0.26 0.19
Sex -4.43 -6.10 4.09 4.32 -0.13 -0.18 -1.08 -1.41 0.28 0.16
Smoking -5.79 -6.31 4.25 4.42 -0.14 -0.15 -1.36 -1.43 0.18 0.16
Diabetes 2.51 3.69 6.48 6.82 0.04 0.06 0.39 0.54 0.70 0.59
Dyslipidemia -3.16 -1.86 6.97 7.27 -0.04 -0.03 -0.45 -0.26 0.65 0.80
R-square (SBP/DBP)=0.212/0.152; Adjusted R-square (SBP/DBP)=0.156/0.091. Cut-off values of LVMI ≥125 g/m2 (M) and ≥110 g/m2 (W). ABP - ambulatory blood pressure;  
B - blood; DBP - diastolic blood pressure; HBP - home blood pressure; SBP - systolic blood pressure
Table 3B. Regression analysis for predictors of LVMI [≥125 g/m2 (M) or ≥110 g/m2 (W)] using ABP and other variables
Her et al.
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Previous study of hypertensive patients in primary care 
reported significant correlations of systolic HBP and daytime 
ABP with both LVMI and AER (16). Other study showed that the 
addition of nighttime HBP to other BP measurements improves 
the association of BP with hypertensive subclinical TOD such as 
LVMI and urine AER (13). In common with previous studies, the 
results of our study showed that ABP and HBP measurements 
are much more closely related to hypertension related TOD than 
OBP measurements. 
In particular, HBP measurements showed a consistent rela-
tionship with many indices of subclinical TOD such as LVMI, 
AER, and PWV. Nevertheless systolic HBP needed a relatively 
small number of measurements, it showed better predictive 
power than 24 hours ABP for PWV. It might be attributed that 
HBP measurements are usually taken under more standardized 
conditions of setting, activity and posture at home after few 
minutes sitting rest. Also, a consistent finding in this analysis 
was that systolic HBP was more closely associated with the 
indices of subclinical TOD than diastolic HBP, which is in line 
with the previous results on the cardiovascular risk associated 
with systolic hypertension (27). In short, the outcome of this 
study may be another objective evidence on the value of HBP 
measurements in the prediction of hypertension induced TOD.
Furthermore, our study showed high systolic HBPV and 24 
hours systolic ABPV have significant correlation with TOD. BPV is 
the result of complex interaction between external environmental 
stimuli and cardiovascular control mechanisms (28). BPV has 
been shown to rise with high levels of blood pressure and be cor-
related with TOD, independent of absolute blood pressure values 
(29). Previous studies have shown a direct association between 
increased 24 hour systolic ABPV and higher incidence of cardio-
vascular complications in patients with treated hypertension after 
accounting for the greater risk due to the elevated mean BP levels 
(30). Also, recent study showed higher ABPV was associated with 
early depressed LV systolic function in newly diagnosed untreated 
hypertensive patients (31). Although the importance of BPV as an 
independent risk factor remains controversial (32, 33), our study 
may be possibly included as one of the prospective pilot studies 
which handle BPV and TOD in untreated hypertensive.
Study limitations
Our study has some limitations. First, two OBP measure-
ments were performed during each visit, and ABP monitoring 
was performed only once. Therefore, we cannot exclude the 
possibility of different results, if a larger number of OBP mea-
 Unstandardized coefficient Standardized 
  coefficient
 B SE Beta t P value
 SBP DBP SBP DBP SBP DBP SBP DBP SBP DBP
HBP 0.41 0.35 0.13 0.17 0.31 0.20 3.17 2.00 0.002 0.049
Age 0.04 0.11 0.12 0.12 0.03 0.10 0.33 0.91 0.74 0.37
Sex 11.79 10.37 3.39 3.45 0.37 0.33 3.48 3.01 0.0008 0.004
Smoking 3.03 2.21 3.75 3.90 0.079 0.06 0.81 0.57 0.42 0.57
Diabetes 18.08 19.11 5.73 6.00 0.30 0.32 3.16 3.19 0.0022 0.002
Dyslipidemia 2.57 2.36 6.20 6.44 0.04 0.04 0.41 0.37 0.68 0.71
R - square (SBP/DBP)=0.290/0.241; Adjusted R-square (SBP/DBP)=0.239/0.186. AER - albumin excretion rate; B - blood; DBP - diastolic blood pressure; F - female; HBP - home blood 
pressure; M - male; SBP - systolic blood pressure; SE - standard error
Table 4A. Regression analysis for predictors of AER [≥22 (M) or ≥31 (F) mg/g Cr] using HBP and other variables
 Unstandardized coefficient Standardized 
  coefficient
 B SE Beta t P value
 SBP DBP SBP DBP SBP DBP SBP DBP SBP DBP
ABP, 24 h 0.34 0.38 0.14 0.18 0.26 0.24 2.46 2.11 0.02 0.04
Age 0.08 0.10 0.12 0.13 0.07 0.08 0.68 0.79 0.50 0.43
Sex 13.20 13.09 3.74 3.87 0.41 0.41 3.53 3.39 0.001 0.001
Smoking 2.80 2.33 3.84 3.89 0.07 0.06 0.73 0.60 0.47 0.55
Diabetes 18.35 19.48 5.87 6.00 0.30 0.32 3.13 3.25 0.002 0.002
Dyslipidemia 0.89 1.91 6.30 6.39 0.01 0.03 0.14 0.30 0.89 0.77
R - square (SBP/DBP)=0.259/0.245; Adjusted R-square (SBP/DBP)=0.205/0.191. ABP - ambulatory blood pressure; AER - albumin excretion rate; B - blood; DBP - diastolic blood 
pressure; F - female; M - male; SBP - systolic blood pressure; SE - standard error
Table 4B. Regression analysis for predictors of AER [≥22 (M) or ≥31 (F) mg/g Cr] using ABP and other variables
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surements or ABP monitoring were obtained. Second, our 
study focused on a limited number of patients. Because of 
the low values of PWV and the relatively small percentage of 
patients with LVH and microalbuminuria, the sample size was 
relatively small. Thus, caution is warranted that our study 
population might not be representative of the general hyper-
tensive patients in clinical practice. A further study including 
a larger number of patients with more severe hypertension 
and longer duration may be needed for more precise conclu-
sions.
Conclusion
In conclusion, HBP measurements are more closely associated 
with hypertension related TOD compared with OBP measurements 
in untreated hypertensive. This study suggests that HBP is as good 
 Unstandardized coefficient Standardized 
  coefficient
 B SE Beta t P value
 SBP DBP SBP DBP SBP DBP SBP DBP SBP DBP
HBP 8.15 2.40 8.15 2.87 0.35 0.08 3.77 0.84 0.001 0.41
Age 8.84 10.37 8.84 2.09 0.46 0.54 4.49 4.95 <.001 <.001
Sex 21.89 -20.47 21.89 58.90 0.04 -0.04 0.40 -0.35 0.69 0.73
Smoking 60.82 60.68 60.82 73.97 0.09 0.08 0.90 0.82 0.37 0.41
Diabetes 159.09 201.43 159.09 115.43 0.14 0.17 1.51 1.75 0.13 0.09
Dyslipidemia -22.99 -30.95 -22.99 115.04 -0.02 -0.03 -0.22 -0.27 0.83 0.79
R-square (SBP/DBP)=0.439/0.336; Adjusted R-square (SBP/DBP)=0.393/0.281. B - blood; DBP - diastolic blood pressure; HBP - home blood pressure; PWV-pulse-wave velocity; SBP - 
systolic blood pressure; SE - standard error
Table 5A. Regression analysis for predictors of PWV using HBP and other variables
 Unstandardized coefficient Standardized 
  coefficient
 B SE Beta t P value
 SBP DBP SBP DBP SBP DBP SBP DBP SBP DBP
ABP, 24hrs 7.10 6.41 2.29 2.99 0.32 0.23 3.10 2.14 0.003 0.04
Age 9.57 10.02 1.99 2.05 0.50 0.52 4.80 4.89 <.0001 <.0001
Sex 54.88 33.47 61.14 63.53 0.11 0.06 0.90 0.53 0.37 0.60
Smoking 52.49 50.04 69.32 71.90 0.07 0.07 0.76 0.70 0.45 0.49
Diabetes 171.46 214.05 107.90 111.95 0.15 0.18 1.59 1.91 0.12 0.06
Dyslipidemia -39.16 -20.22 107.71 111.68 -0.03 -0.02 -0.36 -0.18 0.72 0.86
R-square (SBP/DBP)=0.407/0.369; Adjusted R-square (SBP/DBP)=0.359/0.317. ABP - ambulatory blood pressure; B - blood;  DBP - diastolic blood pressure; PWV-pulse-wave velocity;  
SBP - systolic blood pressure; SE - standard error
Table 5B. Regression analysis for predictors of PWV using ABP and other variables
Blood pressure variability LVMI, g/m2 AER, mg/gCr PWV, m/sec IMT, mm
Home
Systolic / Diastolic BPV 0.10/0.08 0.15/0.01 0.30**/0.04 0.24*/0.10
Ambulatory
24 hours
Systolic / Diastolic BPV 0.25*/0.14 0.08/0.05 -0.02/-0.13 0.11/-0.01
Awake
Systolic / Diastolic BPV 0.18/0.08 0.16/0.08 -0.01/-0.11 0.14/0.02
Asleep
Systolic / Diastolic BPV 0.30**/0.24* -0.10/0.06 0.04/0.02 0.02/0.08
BPV - blood pressure variability; *P <0.05; **P<0.01
Table 6. Correlation coefficients between BP variability and TOD
Her et al.
Home blood pressure Anadolu Kardiyol Derg 2014; 14: 711-8716
as ABP monitoring and superior to the conventional OBP measure-
ments in regard to their association with subclinical TOD assessed 
by LVMI, AER, and PWV. We expect that HBP measurements would 
give valuable information on the cardiovascular TOD in hyperten-
sive patients in addition to ABP monitoring.
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